Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Elly Lugtenburg; I Avivi; H Berenschot; O Ilhan; JP Marolleau; A Nagler; A Rueda; M Tani; M Turgut; S Osborne; R Smith; M Pfreundschuh

doi:10.3324/haematol.2017.173583

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Elly Lugtenburg, I Avivi, H Berenschot, O Ilhan, JP Marolleau, A Nagler, A Rueda, M Tani, M Turgut, S Osborne, R Smith, M Pfreundschuh

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

6 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	1913-1922
Number of pages	10
Journal	Haematologica
Volume	102
Issue number	11
DOIs	https://doi.org/10.3324/haematol.2017.173583
Publication status	Published - 2017

Access to Document

10.3324/haematol.2017.173583

REPUB_108266.pdfFinal published version, 1.07 MB

http://hdl.handle.net/1765/108266

Cite this

Lugtenburg, E., Avivi, I., Berenschot, H., Ilhan, O., Marolleau, JP., Nagler, A., Rueda, A., Tani, M., Turgut, M., Osborne, S., Smith, R., & Pfreundschuh, M. (2017). Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica, 102(11), 1913-1922. https://doi.org/10.3324/haematol.2017.173583

@article{a3d41c7a9a6b457c897963656f50b785,

title = "Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study",

author = "Elly Lugtenburg and I Avivi and H Berenschot and O Ilhan and JP Marolleau and A Nagler and A Rueda and M Tani and M Turgut and S Osborne and R Smith and M Pfreundschuh",

year = "2017",

doi = "10.3324/haematol.2017.173583",

language = "Undefined/Unknown",

volume = "102",

pages = "1913--1922",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "11",

}

Lugtenburg, E, Avivi, I, Berenschot, H, Ilhan, O, Marolleau, JP, Nagler, A, Rueda, A, Tani, M, Turgut, M, Osborne, S, Smith, R & Pfreundschuh, M 2017, 'Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study', Haematologica, vol. 102, no. 11, pp. 1913-1922. https://doi.org/10.3324/haematol.2017.173583

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. / Lugtenburg, Elly; Avivi, I; Berenschot, H et al.
In: Haematologica, Vol. 102, No. 11, 2017, p. 1913-1922.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

AU - Lugtenburg, Elly

AU - Avivi, I

AU - Berenschot, H

AU - Ilhan, O

AU - Marolleau, JP

AU - Nagler, A

AU - Rueda, A

AU - Tani, M

AU - Turgut, M

AU - Osborne, S

AU - Smith, R

AU - Pfreundschuh, M

PY - 2017

Y1 - 2017

U2 - 10.3324/haematol.2017.173583

DO - 10.3324/haematol.2017.173583

M3 - Article

SN - 0390-6078

VL - 102

SP - 1913

EP - 1922

JO - Haematologica

JF - Haematologica

IS - 11

ER -